Prelude Therapeutics (NASDAQ:PRLD) Announces Quarterly Earnings Results

Prelude Therapeutics (NASDAQ:PRLD) issued its earnings results on Tuesday. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.13, FiscalAI reports. The firm had revenue of $5.64 million during the quarter, compared to analysts’ expectations of $20.50 million.

Prelude Therapeutics Stock Performance

PRLD opened at $3.09 on Tuesday. Prelude Therapeutics has a 52-week low of $0.61 and a 52-week high of $4.22. The stock has a market capitalization of $194.27 million, a PE ratio of -2.10 and a beta of 0.79. The stock’s 50 day moving average price is $2.40 and its 200-day moving average price is $1.83.

Institutional Trading of Prelude Therapeutics

Several large investors have recently added to or reduced their stakes in PRLD. AQR Capital Management LLC increased its position in Prelude Therapeutics by 170.7% during the 1st quarter. AQR Capital Management LLC now owns 33,823 shares of the company’s stock valued at $26,000 after purchasing an additional 21,330 shares during the period. Marshall Wace LLP bought a new stake in shares of Prelude Therapeutics during the 2nd quarter valued at about $34,000. XTX Topco Ltd boosted its stake in shares of Prelude Therapeutics by 72.4% during the 2nd quarter. XTX Topco Ltd now owns 42,573 shares of the company’s stock valued at $34,000 after purchasing an additional 17,873 shares in the last quarter. Shay Capital LLC purchased a new position in shares of Prelude Therapeutics during the second quarter valued at about $61,000. Finally, Jane Street Group LLC bought a new position in Prelude Therapeutics in the second quarter worth about $74,000. Institutional investors own 79.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on PRLD shares. Weiss Ratings restated a “sell (d-)” rating on shares of Prelude Therapeutics in a report on Thursday, January 22nd. Wall Street Zen cut shares of Prelude Therapeutics from a “buy” rating to a “hold” rating in a research report on Sunday, January 18th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Prelude Therapeutics presently has an average rating of “Hold” and an average target price of $4.00.

About Prelude Therapeutics

Prelude Therapeutics Incorporated is a clinical-stage precision medicine company focused on the discovery and development of small molecule therapies for genetically defined oncology targets. By leveraging a chemical biology approach, the company aims to deliver targeted treatments that address key drivers of cancer cell growth and survival. Prelude’s pipeline emphasizes novel inhibitors designed to engage molecular pathways validated by both preclinical and clinical evidence.

Among Prelude’s lead programs is PRT2527, a selective PI3K‐alpha/delta inhibitor in Phase 1 clinical trials for solid tumors harboring PIK3CA and other pathway mutations.